IL6 and metabolic dysfunction-associated steatotic liver disease: As evidenced from clinical trials [43,44,45], the protective action of T3 against NAFLD is the culmination of multiple mechanisms, such as anti-inflammation (reduced IL-6 and TNFα) and antioxidant (reduced MDA) effects and correction of metabolic derangements.